| Biomarker ID | 1414 |
| PMID | 24741114 |
| Year | 2014 |
| Biomarker | POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Agressive Vs Non Agressive PCa |
| Type of Biomarker | Prognostic |
| Cohort | 25 patients with Metastatic Prostate Cancer (PCa); 10 normal samples; 24 Non Agressive PCa patients and 16 agressive PCa patients were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | SWATH Mass Spectrometry |
| Clinical | No |
| Remarks | Agressive PCa: Patients with Gleason scores of 8 or 9 and Gleason scores of 7 from patients who either died of cancer metastasis within 6 years of surgery or were positive for metastatic tumor at the time of surgery |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |